Global Information
회사소개 | 문의 | 비교리스트

Chong Kun Dang Pharmaceutical Corp. : 제품 파이프라인 리뷰

Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 224658
페이지 정보 영문 63 Pages
가격
US $ 1,500 ₩ 1,812,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,625,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,438,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Chong Kun Dang Pharmaceutical Corp. : 제품 파이프라인 리뷰 Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016
발행일 : 2016년 12월 페이지 정보 : 영문 63 Pages

Chong Kun Dang Pharmaceutical Corp.는 벌크약, 처방약, 시판약과 비타민, 샴푸, 염모제, 에어졸, 홈매트, 모기향 등의 제품을 제조, 도매, 수출입하고 있는 제약회사입니다. 당사의 중앙연구소에서는 종양학, 면역학, 심혈관, 대사성 질환, 감염증, 중추신경계 질환, 호흡기 질환 분야의 치료제 연구, 화학적 연구 및 신약 개발에 참여하고 있습니다.

Chong Kun Dang Pharmaceutical Corp.의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

Chong Kun Dang Pharmaceutical Corp.의 기본 정보

Chong Kun Dang Pharmaceutical Corp.의 개요

  • 주요 정보
  • 기업 정보

Chong Kun Dang Pharmaceutical Corp. : R&D 개요

  • 주요 치료 범위

Chong Kun Dang Pharmaceutical Corp. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독요법
  • 병용요법 모달리티
  • 파트너 제품
    • 파트너 제품/병용요법 모달리티

Chong Kun Dang Pharmaceutical Corp. : 파이프라인 제품 개요

  • 최종 단계 파이프라인 제품
    • 제III상 제품/병용요법 모달리티
  • 임상 단계 파이프라인 제품
    • 제II상 제품/병용요법 모달리티
    • 제I상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 제품/병용요법 모달리티

Chong Kun Dang Pharmaceutical Corp. : 치료제 개요

  • beloranib
  • carvedilol SR
  • CKD-943
  • (amlodipine besylate + candesartan)
  • CKD-941
  • CKD-942
  • CR-845
  • LT-0011
  • CKD-12101
  • CKD-12201
  • CKD-516
  • CKD-519
  • CKD-581
  • CKD-902
  • CKD-903
  • darbepoetin alfa
  • CKD-10101
  • CKD-830
  • CKD-841
  • Drug to Inhibit HDAC6 for Rheumatoid Arthritis
  • Nepodin

Chong Kun Dang Pharmaceutical Corp. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기서별

Chong Kun Dang Pharmaceutical Corp. : 최근의 파이프라인 동향

Chong Kun Dang Pharmaceutical Corp. : 휴지중인 프로젝트

Chong Kun Dang Pharmaceutical Corp. : 본사 및 자회사 소재지

부록

도표

KSM 15.02.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Chong Kun Dang Pharmaceutical Corp - Product Pipeline Review - 2016', provides an overview of the Chong Kun Dang Pharmaceutical Corp's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chong Kun Dang Pharmaceutical Corp, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Chong Kun Dang Pharmaceutical Corp
  • The report provides overview of Chong Kun Dang Pharmaceutical Corp including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chong Kun Dang Pharmaceutical Corp's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chong Kun Dang Pharmaceutical Corp's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Chong Kun Dang Pharmaceutical Corp's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chong Kun Dang Pharmaceutical Corp
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chong Kun Dang Pharmaceutical Corp's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Chong Kun Dang Pharmaceutical Corp Snapshot
    • Chong Kun Dang Pharmaceutical Corp Overview
    • Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Research and Development Overview
    • Key Therapeutic Areas
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products Glance
    • Chong Kun Dang Pharmaceutical Corp - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Chong Kun Dang Pharmaceutical Corp - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Chong Kun Dang Pharmaceutical Corp - Drug Profiles
    • (amlodipine besylate + candesartan cilexetil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + choline fenofibrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (atorvastatin calcium + ezetimibe) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lobeglitazone + metformin hydrochloride XR) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-516 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-519 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-581 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • darbepoetin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • difelikefalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hyaluronate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levocabastine hydrochloride + mometasone furoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nepodin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Analysis
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Target
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Route of Administration
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Molecule Type
    • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action
  • Chong Kun Dang Pharmaceutical Corp - Dormant Projects
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • beloranib
  • Chong Kun Dang Pharmaceutical Corp - Company Statement
  • Chong Kun Dang Pharmaceutical Corp - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Chong Kun Dang Pharmaceutical Corp, Key Facts
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Combination Treatment Modalities in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase III, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase II, 2016
  • Chong Kun Dang Pharmaceutical Corp - Phase I, 2016
  • Chong Kun Dang Pharmaceutical Corp - Preclinical, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Mechanism of Action, 2016
  • Chong Kun Dang Pharmaceutical Corp - Dormant Developmental Projects,2016
  • Chong Kun Dang Pharmaceutical Corp - Discontinued Pipeline Products, 2016
  • Chong Kun Dang Pharmaceutical Corp, Other Locations

List of Figures

  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Indication, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Stage of Development, 2016
  • Chong Kun Dang Pharmaceutical Corp - Monotherapy Products in Pipeline, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Top 10 Target, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Route of Administration, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline by Molecule Type, 2016
  • Chong Kun Dang Pharmaceutical Corp - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q